Conavi Medical Highlights Peer-Reviewed Publication Demonstrating Advantages of Hybrid IVUS-OCT Imaging

Executive Summary

• Conavi Medical announced a peer‑reviewed study in Cardiovascular Research showing its hybrid IVUS‑OCT deep‑learning classifier outperforms single‑modality approaches and expert readers in plaque characterization.
• The company is advancing its next‑generation Novasight imaging system toward FDA regulatory clearance.
• Conavi granted 1,000,000 stock options to CFO Mark Quick at an exercise price of $0.41 per share (VWAP), vesting under the company’s long‑term incentive plan.

Key Details

• Research Publication: “Deep learning-based plaque characterization in hybrid IVUS-OCT images is superior to single-modality deep learning analysis and human experts: head‑to‑head comparison against histology,” published in Cardiovascular Research (European Society of Cardiology).
• Study used IVUS‑OCT images matched with histology from 10 cadaveric human hearts.
• Hybrid IVUS‑OCT deep‑learning classifier achieved higher accuracy than single‑modality IVUS, single‑modality OCT, and expert readers in plaque characterization.
• Clinical Implication: Findings support the clinical and commercial value of Conavi’s hybrid imaging platform for more precise, image‑guided coronary interventions.
• Regulatory Progress: Next‑generation Novasight system has been submitted to the U.S. FDA for regulatory clearance; commercialization preparations are ongoing.
• Stock Option Grant:
• Recipient: Mark Quick, Chief Financial Officer (grant date Feb 10 2026).
• Quantity: 1,000,000 common shares.
• Exercise price: $0.41 per share (five‑day VWAP on grant date).
• Vesting: As per Conavi’s stock option plan; expires ten years from grant date.
• Subject to required regulatory approvals.

Notable Quotes

• “Peer‑reviewed academic research continues to reinforce the clinical value proposition behind Conavi’s technology platform,” said Tom Looby, CEO of Conavi Medical.

Materiality Assessment: Non‑Material – Positive (the announcement provides favorable scientific validation but does not disclose material financial results or transactions).